A detailed history of Neuberger Berman Group LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Neuberger Berman Group LLC holds 123,741 shares of NBIX stock, worth $15.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
123,741
Previous 117,032 5.73%
Holding current value
$15.5 Million
Previous $16.1 Million 5.54%
% of portfolio
0.01%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$130.86 - $143.19 $877,939 - $960,661
6,709 Added 5.73%
123,741 $17 Million
Q1 2024

May 13, 2024

BUY
$130.4 - $143.74 $15.3 Million - $16.8 Million
117,032 New
117,032 $16.1 Million
Q4 2023

Feb 09, 2024

BUY
$106.07 - $132.76 $319,482 - $399,873
3,012 Added 2.72%
113,757 $15 Million
Q3 2023

Nov 14, 2023

BUY
$94.02 - $117.1 $33,377 - $41,570
355 Added 0.32%
110,745 $12.5 Million
Q2 2023

Aug 11, 2023

BUY
$89.53 - $104.87 $9.31 Million - $10.9 Million
103,961 Added 1617.06%
110,390 $10.4 Million
Q1 2023

May 12, 2023

SELL
$94.11 - $123.02 $3,105 - $4,059
-33 Reduced 0.51%
6,429 $650,000
Q4 2022

Feb 13, 2023

SELL
$106.72 - $127.06 $9,177 - $10,927
-86 Reduced 1.31%
6,462 $771,000
Q3 2022

Nov 15, 2022

SELL
$92.03 - $107.81 $105,006 - $123,011
-1,141 Reduced 14.84%
6,548 $696,000
Q2 2022

Aug 15, 2022

BUY
$75.79 - $100.07 $15,688 - $20,714
207 Added 2.77%
7,689 $750,000
Q1 2022

May 13, 2022

BUY
$72.45 - $94.81 $213,582 - $279,499
2,948 Added 65.02%
7,482 $699,000
Q4 2021

Feb 11, 2022

BUY
$79.65 - $106.22 $108,722 - $144,990
1,365 Added 43.07%
4,534 $379,000
Q3 2021

Nov 12, 2021

BUY
$86.18 - $99.03 $2,413 - $2,772
28 Added 0.89%
3,169 $301,000
Q2 2021

Aug 13, 2021

BUY
$89.43 - $102.27 $17,081 - $19,533
191 Added 6.47%
3,141 $305,000
Q1 2021

May 13, 2021

SELL
$87.57 - $119.4 $28,898 - $39,402
-330 Reduced 10.06%
2,950 $287,000
Q4 2020

Feb 10, 2021

BUY
$86.91 - $108.33 $1,651 - $2,058
19 Added 0.58%
3,280 $315,000
Q3 2020

Nov 12, 2020

BUY
$96.16 - $135.15 $31,732 - $44,599
330 Added 11.26%
3,261 $313,000
Q2 2020

Aug 13, 2020

SELL
$85.09 - $130.36 $4.41 Million - $6.76 Million
-51,832 Reduced 94.65%
2,931 $358,000
Q1 2020

May 14, 2020

SELL
$75.11 - $113.76 $437,665 - $662,879
-5,827 Reduced 9.62%
54,763 $4.74 Million
Q4 2019

Feb 12, 2020

SELL
$86.8 - $118.57 $185,318 - $253,146
-2,135 Reduced 3.4%
60,590 $6.51 Million
Q3 2019

Nov 13, 2019

BUY
$83.82 - $101.5 $5.26 Million - $6.37 Million
62,725 New
62,725 $5.65 Million
Q2 2019

Aug 13, 2019

SELL
$72.24 - $91.27 $5.8 Million - $7.33 Million
-80,284 Closed
0 $0
Q1 2019

May 13, 2019

SELL
$69.31 - $91.53 $5.38 Million - $7.11 Million
-77,663 Reduced 49.17%
80,284 $7.07 Million
Q4 2018

Feb 12, 2019

SELL
$68.32 - $124.36 $8.65 Million - $15.7 Million
-126,635 Reduced 44.5%
157,947 $11.3 Million
Q3 2018

Nov 13, 2018

SELL
$98.88 - $125.85 $4.64 Million - $5.9 Million
-46,913 Reduced 14.15%
284,582 $35 Million
Q2 2018

Aug 13, 2018

SELL
$75.3 - $105.99 $2.21 Million - $3.11 Million
-29,300 Reduced 8.12%
331,495 $32.6 Million
Q1 2018

May 08, 2018

SELL
$75.88 - $92.43 $8.8 Million - $10.7 Million
-116,000 Reduced 24.33%
360,795 $29.9 Million
Q4 2017

Feb 14, 2018

BUY
$58.53 - $77.59 $1.26 Million - $1.67 Million
21,500 Added 4.72%
476,795 $37 Million
Q3 2017

Nov 15, 2017

BUY
$47.97 - $61.28 $21.8 Million - $27.9 Million
455,295
455,295 $27.9 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Neuberger Berman Group LLC Portfolio

Follow Neuberger Berman Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Neuberger Berman Group LLC with notifications on news.